Lazard Asset Management
ARRY

Lazard Asset Management’s Array Biopharma Inc ARRY Stock Holding History

Lazard Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,500
Closed -$20K – 1068
2017
Q2 		$20K Buy
+2,500
New +$20.4K ﹤0.01% 884

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Lazard Asset Management's ARRY Position: Q3 2017 in Review

Lazard Asset Management sold out of Array Biopharma Inc (ARRY) in Q3 2017, closing a stake of 2,500 shares — an estimated $20K sold.

Lazard Asset Management first reported a position in ARRY in Q2 2017 and held it in 1 quarter. The position peaked at $20K in Q2 2017. 184 funds tracked by Wall St. Rank hold ARRY as of Q3 2017.

  • Lazard Asset Management reported no remaining Array Biopharma Inc position as of Q3 2017 after selling out during the quarter.
  • Lazard Asset Management sold 2,500 Array Biopharma Inc shares in Q3 2017, an estimated $20K.
  • Lazard Asset Management first reported a position in Array Biopharma Inc in Q2 2017 and held it in 1 quarter.
  • Lazard Asset Management's Array Biopharma Inc position peaked at $20K in Q2 2017.
  • 184 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2017.

Based on Lazard Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.